Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer vaccines

L G Durrant1

  • 1CRC Department of Clinical Oncology, University of Nottingham, City Hospital, UK.

Anti-Cancer Drugs
|December 13, 1997
PubMed
Summary
This summary is machine-generated.

Cancer vaccines target tumor cells by identifying unique antigens. Researchers are developing vaccines against melanoma, colorectal, and breast cancers, with DNA vaccines showing future promise.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Native/citrullinated LL37-specific T-cells help autoantibody production in Systemic Lupus Erythematosus.

Scientific reports·2020
Same author

Post-translational modifications such as citrullination are excellent targets for cancer therapy.

Seminars in immunology·2020
Same author

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer.

British journal of cancer·2012
Same author

Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.

Clinical and experimental immunology·2012
Same author

Single shot tetanus vaccine manufactured by a supercritical fluid encapsulation technology.

International journal of pharmaceutics·2011
Same author

Cancer vaccines.

Methods in molecular medicine·2011

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Improved understanding of immune recognition of cells has identified potential tumor cell targets.
  • Successful melanoma immunotherapies include GM2 ganglioside vaccines and targeting novel antigens (MAGE, BAGE, GAGE).
  • Overexpressed normal differentiation antigens (tyrosinase, Pmel 17, Melan A) are also viable targets for cancer vaccines.

Purpose of the Study:

  • To review current advancements in cancer vaccine development targeting various solid tumors.
  • To highlight promising targets and vaccine strategies for melanoma, colorectal, and breast cancers.
  • To discuss the potential of novel vaccine platforms, such as DNA vaccines.

Main Methods:

  • Review of existing research on tumor antigens and immune recognition.

Related Experiment Videos

  • Analysis of clinical development of vaccines targeting specific cancer antigens.
  • Exploration of emerging vaccine technologies like DNA vaccines.

    • Main Results:

    • Several vaccine candidates targeting melanoma, colorectal, and breast cancer antigens are in clinical development.
    • Novel antigens (MAGE, BAGE, GAGE) and differentiation antigens (tyrosinase, Pmel 17, Melan A) show promise.
    • DNA vaccines offer a potential future direction due to their mechanism of action.

    Conclusions:

    • Targeting tumor-specific and differentiation antigens is a key strategy in cancer vaccine development.
    • Diverse vaccine platforms, including antibody, anti-idiotype, and antigen-based vaccines, are under investigation.
    • DNA vaccines represent a promising future avenue for cancer immunotherapy.